BillionToOne, Inc. (BLLN) Stock Score, Valuation & Financial Research
BillionToOne, Inc. is in the Healthcare sector and Medical - Diagnostics & Research industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 52/100.
Quick answer for BLLN
BillionToOne, Inc. currently has a Wall Street Score of 52/100. The stored market price is $98.77. Its financial score is 73/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What BillionToOne, Inc. does
BillionToOne, Inc. is a specialized diagnostics company that innovates by precisely quantifying biological data to create advanced molecular diagnostic solutions. Central to their operations is a cutting-edge molecular counting platform, meticulously engineered to identify and measure individual DNA molecules, thereby significantly enhancing the precision of disease detection. Their product portfolio includes: UNITY Complete: A non-invasive prenatal screen that assesses a fetus's risk for aneuploidies, recessive genetic conditions, and fetal antigens, all from a simple maternal blood sample. Northstar Select: A liquid biopsy test designed to pinpoint specific mutations present in tumors, encompassing deletions, insertions, and point mutations. Northstar Response: A diagnostic tool that enables continuous tracking of cancer progression through detailed methylation assessment. Established
BLLN financial snapshot
- Wall Street Score:
- 52/100
- Current price:
- $98.77
- Market capitalization:
- $4.54B
- Revenue:
- $397.4M
- Net income:
- $33.5M
- Free cash flow:
- $15.7M
- Cash:
- $548.6M
- Total debt:
- $143.9M
- EPS:
- 0.69
- P/E ratio:
- 143.1x
- Financial score:
- 73/100
- Valuation score:
- 0/100
- Revenue score:
- 45/100
What stands out
- Reported year-over-year revenue growth is +0.3%.
- Free cash flow is $15.7M, showing positive cash generation.
- The balance sheet shows $548.6M of cash versus $143.9M of total debt, leaving more cash than debt.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 73/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-09.
How to research BLLN
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.